Spironolactone CAS 52-01-7

Product Description:

Product Name: Spironolactone CAS NO: 52-01-7

Synonyms:

7α-Acetylthio-17α-hydroxy-3-oxopregn-4-ene-21-carboxylic acid γ-lactone;

S-[(7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate;

7α-Acetylthiospirolactone;

Chemical & Physical Properties:

Appearance: White powder

Assay :≥99.0%

Density: 1.24g/cm3

Boiling Point: 597℃ at 760mmHg

Melting Point: 198-207℃

Flash Point: 302.3℃

Refractive Index: -36 ° (C=1, CHCl3)

Water Solubility: practically insoluble

Stability: Stable under normal temperatures and pressures.

Storage Condition: Keep container closed when not in use. Store in a cool, dry, well-ventilated area away from incompatible substances.

Safety Information:

RTECS: TU4725000

Safety Statements: S53-S22-S36/37/39-S45

HS Code: 2937290090

WGK Germany: 3

Risk Statements: R40; R60

Hazard Code: T

Spironolactone is a potent antagonist of the andro-gen receptor. Target: Andro-gen ReceptorSpironolactone is a potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. 5% topical spironolactone cream acts as an antiandro-gen in human sebaceous glands, competing with DHT receptors and producing a decrease of labelled DHT. At the concentrations used the effect has been only local. No side-effects were recorded during both studies. Patients who received spironolactone had a significant improvement in the symptoms of heart failure, as assessed on the basis of the New York Heart Association functional class (P<0.001). Gynecomastia or breast pain was reported in 10 percent of men who were treated with spironolactone, as compared with 1 percent of men in the placebo group (P<0.001). The incidence of serious hyperkalemia was minimal in both groups of patients.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.